Cost Info and Financial Help With KEYTRUDA® (pembrolizumab)

COST INFO & FINANCIAL HELP

Figuring out what you might pay out of pocket for a prescription medicine can be confusing. What you pay will depend on many factors, including your insurance situation and if there are financial support options available to you. At Merck, we believe that you should be better able to understand what you can expect to pay out of your own pocket for your prescription medicine.

The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $9,869.94. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $19,739.88.* The total cost of KEYTRUDA over the course of treatment is the same, whether given every 3 weeks or every 6 weeks. Most people will not pay the list price, although it may have an impact on your out-of-pocket costs. The amount you pay will depend on many factors, including your insurance situation. The information below will help you better estimate what you may pay for your prescription medicine based on your insurance situation and also cover financial assistance that may be available to you. For the actual out-of-pocket cost of your treatment, talk to your insurance provider, who knows the details of your plan if you have insurance, or contact your oncologist’s office for help.

*The indicated adult dose of KEYTRUDA is either 200 mg given every 3 weeks or 400 mg given every 6 weeks. KEYTRUDA is administered as an intravenous infusion. Your doctor will decide how many treatments you need. The list price does not include other treatment-related costs. The list price is current as of October 2020.

The adult dose given every 6 weeks is approved based on specific types of data showing how this dose works in the body. Studies are ongoing to provide additional information about clinical benefit.

The out-of-pocket costs below do not include the other medicines that you may take with KEYTRUDA or infusion center costs to administer KEYTRUDA or other medicines.

Choose an option below that best describes your insurance situation:

Commercial or private insurance

I have commercial insurance through an employer or a private policy that covers KEYTRUDA

For patients with commercial insurance who received a 200 mg dose, 68% of patients paid no out-of-pocket costs for KEYTRUDA. For those patients who did have out-of-pocket costs, 80% of patients paid between $0 and $375 per infusion, after satisfying their deductible.1

  • What you pay for KEYTRUDA will largely depend on your insurance plan. Each plan has different out-of-pocket costs for the medicines they cover, and most include an annual deductible. If you haven’t met your deductible, you may pay a higher out-of-pocket cost and could pay an amount closer to the list price above, until you meet your deductible.

If you are unable to afford KEYTRUDA, Merck may be able to help. Contact The Merck Access Program at 855-257-3932 (or 855-257-7332 for the hearing impaired).

1 Milliman, Inc., Expected Patient Out-of-Pocket Costs for Keytruda® (pembrolizumab), June 2019. Based on an analysis of 2017 commercial and Medicare claims for 200 mg doses of KEYTRUDA. Commissioned by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. Milliman’s analysis of a patient’s out-of-pocket payments for KEYTRUDA does not include contributions from secondary payers, manufacturer co-pay coupons, or other payments contributing to a patient’s liability due to limitations in its datasets. A patient’s true out-of-pocket payment may be less than the calculated patient liability illustrated in its analysis.

Medicare

I have coverage for KEYTRUDA through Medicare (either through Medicare Advantage or traditional Medicare)

For patients with a Medicare Advantage plan who received a 200 mg dose, 41% of patients paid no out-of-pocket costs for KEYTRUDA. For those patients who did have out-of-pocket costs, 80% of patients paid between $0 and $925 per infusion, after satisfying their deductible. For patients with traditional Medicare and no supplemental coverage (ie, a Medigap or Medicare Supplement plan), 80% of patients paid between $1,000 and $1,950 per infusion, after satisfying their deductible.1 Many traditional Medicare beneficiaries, however, have supplemental coverage through their employer or a Medigap plan.2 This type of coverage often covers most or all of traditional Medicare Part B coinsurance or co-payments.3

  • What you pay for KEYTRUDA will largely depend on your insurance plan. Each Medicare Advantage plan has different out-of-pocket costs for the medicines they cover, and most include an annual deductible. If you haven’t met your deductible, you may pay a higher out-of-pocket cost and could pay an amount closer to the list price above, until you meet your deductible.

If you are unable to afford KEYTRUDA, Merck may be able to help. Contact The Merck Access Program at 855-257-3932 (or 855-257-7332 for the hearing impaired).

1 Milliman, Inc., Expected Patient Out-of-Pocket Costs for Keytruda® (pembrolizumab), June 2019. Based on an analysis of 2017 commercial and Medicare claims for 200 mg doses of KEYTRUDA. Commissioned by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. Milliman’s analysis of a patient’s out-of-pocket payments for KEYTRUDA does not include contributions from secondary payers, manufacturer co-pay coupons, or other payments contributing to a patient’s liability due to limitations in its datasets. A patient’s true out-of-pocket payment may be less than the calculated patient liability illustrated in its analysis.

2 Kaiser Family Foundation. Medigap enrollment and consumer protections vary across states, July 2018. https://www.kff.org/medicare/issue-brief/medigap-enrollment-and-consumer-protections-vary-across-states.

3 Medicare.gov. How to compare Medigap policies. https://www.medicare.gov/supplements-other-insurance/how-to-compare-medigap-policies. Accessed August 1, 2019.

Medicaid

I have coverage for KEYTRUDA through Medicaid

For most people on Medicaid, patient out-of-pocket costs for prescription medicines like KEYTRUDA range from $4 to $8 per infusion.1 Your out-of-pocket costs may vary if you have a higher income. To learn more about Medicaid in your state and find out if you’re eligible, visit https://www.medicaid.gov/medicaid-and-you/index.html.

If you are unable to afford KEYTRUDA, Merck may be able to help. Contact The Merck Access Program at 855-257-3932 (or 855-257-7332 for the hearing impaired).

1Centers for Medicare & Medicaid Services (CMS). Cost sharing out of pocket costs. https://www.medicaid.gov/medicaid/cost-sharing/out-of-pocket-costs/index.html. Accessed August 7, 2019.

No insurance coverage

I don’t have insurance or KEYTRUDA is not covered by my insurance plan

If you don’t have insurance coverage or your insurance does not cover your treatment with KEYTRUDA, you could pay an amount closer to the list price shown above, plus any additional charges depending on where you receive your medicine.

If you are unable to afford KEYTRUDA, Merck may be able to help. Contact The Merck Access Program at 855-257-3932 (or 855-257-7332 for the hearing impaired).

Need more information about whether your insurance provider covers KEYTRUDA or about potential financial assistance options?

If you need further information or help paying for KEYTRUDA (with or without insurance coverage), Merck may be able to help. Contact The Merck Access Program at 855-257-3932 (or 855-257-7332 for the hearing impaired). The Merck Access Program can help answer questions like:

  • Does my insurance cover KEYTRUDA?
  • What are the co-pay assistance options for eligible patients?
  • How can I find out if I’m eligible for the Merck Patient Assistance Program?
    • Merck provides certain of its medicines and adult vaccines for free to eligible patients who do not have prescription drug or health insurance coverage and who, without assistance, cannot afford the medicines and vaccines made by Merck. This is consistent with Merck’s long-held values and tradition of putting patients first.
Visit The Merck Access Program Website for More Information and to Enroll.

Visit The Merck Access Program website for more information and to enroll.

Call 855-257-3932 to Speak to a Merck Access Program Representative

To speak to a Merck Access Program representative:

FDA-Approved Indications

KEYTRUDA is a prescription medicine used to treat:

  • a kind of skin cancer called melanoma.
    • It may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma), or
    • It may be used to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
  • a kind of lung cancer called non–small cell lung cancer (NSCLC).
    • It may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC) and is a type called “nonsquamousand your tumor does not have an abnormal “EGFR” or “ALK” gene.
    • It may be used with the chemotherapy medicines carboplatin and either paclitaxel or paclitaxel protein-bound as your first treatment when your lung cancer has spread (advanced NSCLC), and is a type called “squamous.”
    • It may be used alone as your first treatment when your lung cancer has not spread outside your chest (stage III) and you cannot have surgery or chemotherapy with radiation, or your NSCLC has spread to other areas of your body (advanced NSCLC), and your tumor tests positive for “PD-L1and does not have an abnormal “EGFR” or “ALK” gene.
    • It may also be used alone for advanced NSCLC if you have tried chemotherapy that contains platinum and it did not work or is no longer working and, your tumor tests positive for “PD-L1and if your tumor has an abnormal “EGFR” or “ALK” gene, you have also received an “EGFR” or “ALK” inhibitor medicine that did not work or is no longer working.
  • a kind of cancer called head and neck squamous cell cancer (HNSCC).
    • It may be used with the chemotherapy medicines fluorouracil and a platinum as your first treatment when your head and neck cancer has spread or returned and cannot be removed by surgery.
    • It may be used alone as your first treatment when your head and neck cancer has spread or returned and cannot be removed by surgery, and your tumor tests positive for “PD-L1.”
    • It may be used alone when your head and neck cancer has spread or returned, and you have received chemotherapy that contains platinum and it did not work or is no longer working.
  • a kind of cancer called classical Hodgkin lymphoma (cHL). It may be used
    • in adults when:
      • your cHL has returned or
      • you have tried a treatment and it did not work, or
    • in children when:
      • you have tried a treatment and it did not work, or
      • your cHL has returned after you received 2 or more types of treatment.
  • a kind of cancer called primary mediastinal B-cell lymphoma (PMBCL). It may be used in adults and children when you have tried a treatment and it did not work, or your PMBCL has returned after you received 2 or more types of treatment.
  • a kind of bladder and urinary tract cancer called urothelial carcinoma.
    • It may be used when your cancer has not spread to nearby tissue in the bladder, but is at high-risk for spreading (high-risk, non-muscle invasive bladder cancer [NMIBC]) and when your tumor is a type called “carcinoma in situ” (CIS), and you have tried treatment with Bacillus Calmette-Guerin (BCG) and it did not work, and you are not able to or have decided not to have surgery to remove your bladder.
    • It may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer), and you are not able to receive chemotherapy that contains a medicine called cisplatin, and your tumor tests positive for “PD-L1,” or you are not able to receive a medicine called cisplatin or carboplatin.
      This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
    • It may be used when your bladder or urinary tract cancer has spread or cannot be removed by surgery (advanced urothelial cancer) and you have received chemotherapy that contains platinum, and it did not work or is no longer working.
  • a kind of cancer that is shown by a laboratory test to be a microsatellite instability-high (MSI-H) or a mismatch repair deficient (dMMR) solid tumor. It may be used in adults and children to treat:
    • cancer that has spread or cannot be removed by surgery (advanced cancer), and
    • has progressed following treatment, and you have no satisfactory treatment options, or
    • you have colon or rectal cancer, and you have received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan but it did not work or is no longer working.
  • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
    It is not known if KEYTRUDA is safe and effective in children with MSI-H cancers of the brain or spinal cord (central nervous system cancers).
  • a kind of cancer called colon or rectal cancer. It may be used as your first treatment when your cancer:
    • has spread or cannot be removed by surgery (advanced colon or rectal cancer), and
    • has been shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
  • a kind of stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that tests positive for “PD-L1.” It may be used when your stomach cancer:
    • has returned or spread (advanced gastric cancer), and
    • you have received 2 or more types of chemotherapy including fluoropyrimidine and chemotherapy that contains platinum, and it did not work or is no longer working, and
    • if your tumor has an abnormal “HER2/neu” gene, you also received a HER2/neu‑targeted medicine and it did not work or is no longer working.
  • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
  • a kind of cancer called squamous cell carcinoma of the esophagus. It may be used when:
    • your cancer has returned or spread (advanced esophageal cancer), and
    • your tumor tests positive for “PD-L1,” and you have received one or more types of treatment and it did not work or is no longer working.
  • a kind of cancer called cervical cancer that tests positive for “PD-L1.” It may be used when your cervical cancer has returned or has spread or cannot be removed by surgery (advanced cervical cancer), and you have received chemotherapy, and it did not work or is no longer working.
  • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
  • a kind of liver cancer called hepatocellular carcinoma. It may be used after you have received the medicine sorafenib.
  • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
  • a kind of skin cancer called Merkel cell carcinoma (MCC) in adults and children. It may be used when your cancer has spread or returned.
  • This use is approved based on how many patients responded to treatment and how long they responded. Studies are ongoing to provide additional information about clinical benefit.
  • a kind of kidney cancer called renal cell carcinoma (RCC). It may be used with the medicine axitinib as your first treatment when your kidney cancer has spread or cannot be removed by surgery (advanced RCC).
  • a kind of skin cancer called cutaneous squamous cell carcinoma (cSCC). It may be used when your skin cancer has returned or spread, and cannot be cured by surgery or radiation.
  • a kind of cancer called triple-negative breast cancer (TNBC). It may be used with chemotherapy medicines when your breast cancer:
    • has returned and cannot be removed by surgery or has spread, and
    • tests positive for “PD-L1.”
  • This use is approved based on the amount of time until patients’ disease got worse. Studies are ongoing to provide additional information about clinical benefit.

PD-L1 = programmed death ligand 1;
EGFR = epidermal growth factor receptor;
ALK = anaplastic lymphoma kinase;
HER2/neu = human epidermal growth factor receptor 2.

Important Safety Information

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen any time during treatment or even after your treatment has ended.

Call or see your health care provider right away if you develop any signs or symptoms of the following problems or if they get worse. These are not all of the signs and symptoms of immune system problems that can happen with KEYTRUDA:

Lung problems: cough, shortness of breath, or chest pain.

Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; or severe stomach-area (abdomen) pain or tenderness.

Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); or bleeding or bruising more easily than normal.

Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness.

Kidney problems: decrease in the amount of your urine; blood in your urine; swelling of your ankles; loss of appetite.

Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in your mouth or in your nose, throat, or genital area; fever or flu-like symptoms; swollen lymph nodes.

Problems can also happen in other organs and tissues. Signs and symptoms of these problems may include: chest pain; irregular heartbeat; shortness of breath; swelling of ankles; confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs; double vision; blurry vision; sensitivity to light; eye pain; changes in eyesight; persistent or severe muscle pain or weakness; muscle cramps; low red blood cells; bruising.

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feeling like passing out, fever, and back pain.

Rejection of a transplanted organ: Your health care provider should tell you what signs and symptoms you should report and they will monitor you, depending on the type of organ transplant that you have had.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with KEYTRUDA. Your health care provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your health care provider will check you for these problems during treatment with KEYTRUDA. They may treat you with corticosteroid or hormone replacement medicines. They may also need to delay or completely stop treatment with KEYTRUDA if you have severe side effects.

Before you receive KEYTRUDA, tell your health care provider if you have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or have had or plan to have a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic); have had radiation treatment in your chest area; have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome.

If you are pregnant or plan to become pregnant, tell your health care provider. KEYTRUDA can harm your unborn baby. If you are able to become pregnant, you will be given a pregnancy test before you start treatment. Use effective birth control during treatment and for at least 4 months after your final dose of KEYTRUDA. Tell them right away if you think you may be pregnant or you become pregnant during treatment with KEYTRUDA.

Tell your health care provider if you are breastfeeding or plan to breastfeed. It is not known if KEYTRUDA passes into your breast milk. Do not breastfeed during treatment with KEYTRUDA and for 4 months after your final dose of KEYTRUDA.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Common side effects of KEYTRUDA when used alone include feeling tired; pain, including pain in muscles, bones or joints and stomach area (abdominal) pain; decreased appetite; itching; diarrhea; nausea; rash; fever; cough; shortness of breath; and constipation.

In children, when KEYTRUDA is used alone, fever, vomiting, upper respiratory tract infection, headache, and low levels of white blood cells and red blood cells (anemia) are more common than in adults.

Common side effects of KEYTRUDA when given with certain chemotherapy medicines include feeling tired or weak; nausea; constipation; diarrhea; decreased appetite; rash; vomiting; cough; trouble breathing; fever; hair loss; inflammation of the nerves that may cause pain, weakness, and paralysis in the arms and legs; swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; mouth sores; and headache.

Common side effects of KEYTRUDA when given with axitinib include diarrhea; feeling tired or weak; high blood pressure; liver problems; low levels of thyroid hormone; decreased appetite; blisters or rash on the palms of your hands and soles of your feet; nausea; mouth sores or swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina; hoarseness; rash; cough; and constipation.

These are not all the possible side effects of KEYTRUDA. Talk to your health care provider for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read the accompanying Medication Guide for KEYTRUDA and discuss it with your doctor. The physician Prescribing Information also is available.